Sobi Pays $1.5bn for Arthrosi to Grow in Gout

Sobi pays $1.5bn for Arthrosi to grow in gout

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage testing for gout.

Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.

STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of…

Sobi strengthens gout pipeline with Arthrosi acquisition - European Biotechnology Magazine

Sobi AB has completed the US$1.5bn acquisition of Chinese Arthrosi Therapeutics Ltd. Its lead candidate, pozdeutinurad, a URAT1 inhibitor for gout, is in pivotal global Phase-III trials, with China licensing targeting approval by 2028. Sobi acquires Arthrosi Therapeutics and secures pozdeutinurad, a URAT1 inhibitor for gout, with global Phase-3 trials and China licensing.

Swedish Orphan Biovitrum Acquires Arthrosi Therapeutics in $1.5 Billion Deal to Secure Phase III Gout Drug

Swedish Orphan Biovitrum (SOBI) has announced the acqui […] The post Swedish Orphan Biovitrum Acquires Arthrosi Therapeutics in $1.5 Billion Deal to Secure Phase III Gout Drug first appeared on GeneOnline News. The post Swedish Orphan Biovitrum Acquires Arthrosi Therapeutics in $1.5 Billion Deal to Secure Phase III Gout Drug appeared first on GeneOnline News.

Sobi buys Arthrosi to expand gout treatment pipeline

Sobi will purchase for Arthrosi Skr9.1bn ($950m) in cash. Additional payments of up to Skr5.3bn ($550m) may be made based on clinical, regulatory and sales milestones. The acquisition The post Sobi buys Arthrosi to expand gout treatment pipeline appeared first on Pharmaceutical Business review.

Sobi to buy gout biotech Arthrosi for $950M upfront

Sobi plans to buy Arthrosi Therapeutics, a Phase 3 gout biotech, for $950 million upfront and as much as $550 million in additional milestones, the Swedish drugmaker said Saturday. The Arthrosi ...